Payment overview · 2025
General Payments
$270.85
14 reported records · 10 companies
Healthcare provider profile · identity verified
Gregory N Henson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NORTH LITTLE ROCK, AR · NPI 1437135191
Verified facts
What the public records show
CMS Open Payments records show Gregory N Henson, M.D. received $270.85 in general payments during 2025 across 14 reported records.
Lilly USA, LLC accounted for 18.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Paxlovid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50.91 | 18.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.12 | 13.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.93 | 12.2% | 1 | 2025 |
| TELA Bio, Inc. | Unresolved — no canonical attribution shown | $31.94 | 11.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.80 | 10.6% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $20.65 | 7.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.85 | 7.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.78 | 6.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.84 | 6.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.03 | 5.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $270.85 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $50.91 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $50.91 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $32.93 | 1 | 2025 |
Source payment records
|
|||||
| OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) Normalized: ovitex reinforced bioscaffold with permanent polymer ovitex |
Device | TELA Bio, Inc. | $31.94 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.80 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $20.65 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.03 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.03 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 44 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 59 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 14 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
92 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
44 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 528 | 152 |
| Amlodipine Besylate | Amlodipine Besylate | 313 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 298 | 77 |
| Omeprazole | Omeprazole | 289 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 226 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 202 | 53 |
| Gabapentin | Gabapentin | 158 | 40 |
| Irbesartan | Irbesartan | 147 | 30 |
| Montelukast Sodium | Montelukast Sodium | 145 | 36 |
| Losartan Potassium | Losartan Potassium | 139 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | 36 |
| Tramadol Hcl | Tramadol Hcl | 132 | 42 |
| Alprazolam | Alprazolam | 131 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 129 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 128 | 35 |
| Metformin Hcl | Metformin Hcl | 112 | 34 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 109 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 106 | 38 |
| Atenolol | Atenolol | 100 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 99 | 29 |
| Jardiance | Empagliflozin | 92 | 17 |
| Lisinopril | Lisinopril | 92 | 29 |
| Potassium Chloride | Potassium Chloride | 89 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 87 | 19 |
| Famotidine | Famotidine | 85 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 85 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 85 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 16 |
| Metformin Hcl Er | Metformin Hcl | 83 | 23 |
| Meloxicam | Meloxicam | 78 | 27 |
| Simvastatin | Simvastatin | 78 | 21 |
| Glimepiride | Glimepiride | 76 | 19 |
| Sertraline Hcl | Sertraline Hcl | 76 | 24 |
| Furosemide | Furosemide | 75 | 24 |
| Carvedilol | Carvedilol | 71 | 21 |
| Allopurinol | Allopurinol | 61 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 26 |
| Ozempic | Semaglutide | 59 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 23 |
| Ezetimibe | Ezetimibe | 58 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | 11 |
| Clonazepam | Clonazepam | 55 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 13 |
| Spironolactone | Spironolactone | 55 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 16 |
| Trulicity | Dulaglutide | 50 | suppressed |
| Lorazepam | Lorazepam | 48 | suppressed |
| Finasteride | Finasteride | 47 | 12 |
| Eliquis | Apixaban | 44 | 14 |
| Sucralfate | Sucralfate | 44 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 40 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 37 | 11 |
| Synthroid | Levothyroxine Sodium | 35 | 11 |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 11 |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Topiramate | Topiramate | 32 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 12 |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Prednisone | Prednisone | 27 | 20 |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Cefdinir | Cefdinir | 20 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 13 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 15 |
| Glipizide | Glipizide | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Constulose | Lactulose | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 14 |
| Azithromycin | Azithromycin | 15 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 15 |
| Indapamide | Indapamide | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Acetazolamide | Acetazolamide | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 11 |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Baclofen | Baclofen | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $270.85 · 14 records | Lilly USA, LLC | ABRYSVO, ACCRUFER, AREXVY, CAPLYTA, COMIRNATY, ELIQUIS, LEQVIO, MOUNJARO, NURTEC ODT, OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex), Ozempic, PAXLOVID, PREVNAR 20, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error